Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular or Subcutaneous Route in Participants Aged 65 Years and Older in Japan
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors sanofi pasteur
- 26 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2017 Status changed from not yet recruiting to recruiting.
- 02 Aug 2017 New trial record